140 related articles for article (PubMed ID: 6355949)
1. [Therapeutic results with aclacinomycin A in recurring acute leukemias].
Mitrou PS
Onkologie; 1983 Aug; 6(4):192-4. PubMed ID: 6355949
[TBL] [Abstract][Full Text] [Related]
2. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
[TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory acute leukemia with aclacinomycin-A.
Takahashi I; Hara M; Adachi T; Takaoka K; Sakano M; Lai M; Kohi F; Yorimitsu S; Tokioka M; Kitajima K; Kimura I; Sanada H
Acta Med Okayama; 1980 Nov; 34(5):349-54. PubMed ID: 6449134
[TBL] [Abstract][Full Text] [Related]
4. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
8. [Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
Beck JD
Monatsschr Kinderheilkd; 1986 Aug; 134(8):547-9. PubMed ID: 3464845
[TBL] [Abstract][Full Text] [Related]
9. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Sampi K; Honda T; Hayashi Y; Hattori M
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
[TBL] [Abstract][Full Text] [Related]
10. [Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Kobayashi M; Tahara T
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1473-9. PubMed ID: 6575727
[TBL] [Abstract][Full Text] [Related]
11. Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Fink FM; Grümayer ER; Kardos G; Revesz T; Gadner H; Schuler D
Haematol Blood Transfus; 1987; 30():393-8. PubMed ID: 3305209
[No Abstract] [Full Text] [Related]
12. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
[TBL] [Abstract][Full Text] [Related]
13. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
Sampi K; Sakurai M; Kaneko Y; Hattori M
Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
[TBL] [Abstract][Full Text] [Related]
15. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
Ishige K; Takagi T; Oguro M
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1475-9. PubMed ID: 6588925
[TBL] [Abstract][Full Text] [Related]
17. Aclacinomycin-A in the induction treatment of childhood AML.
Fink FM; Grümayer ER; Kardos G; Revesz T; Gadner H; Schuler D
Onkologie; 1986 Jun; 9(3):154-5. PubMed ID: 3528963
[TBL] [Abstract][Full Text] [Related]
18. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
Marie JP; Thevenin D; Zittoun R
Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
[TBL] [Abstract][Full Text] [Related]
19. Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias.
Mitrou PS
Eur J Haematol Suppl; 1987; 47():59-66. PubMed ID: 3471526
[No Abstract] [Full Text] [Related]
20. Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center.
Sampi K; Sakurai M; Kaneko Y; Hattori M
Anticancer Res; 1985; 5(3):293-6. PubMed ID: 4015043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]